- The stock is currently traded in the range of Rs.600.
- Company's 3QFY13 sales beat 6% and PAT beat 16% largely driven by greater than expected Tricor sales in the US and forex gains of Rs.23 crore.
- Tricor is likely to see more competition and hence, current sales may not be sustainable.
- Strong flu season in the US lifted US branded sales by 27%.
- The company plans to launch 50 products in the US over the next few years, which is expected to help the US core business to grow by more than 30%.
- Indian growth is expected to be over 18% in FY14.
- US-brands should continue to be driven by Suprax as Antara faces growth challenges from generic entry in competing products.
- It seems that the positives are priced in the current stock price and upside looks limited. Hence, 'hold' rating is maintained.